Form 4: Corcept Therapeutics Executive Exercises Options and Sells Shares to Cover Costs

Gary Charles Robb, Chief Business Officer of Corcept Therapeutics, exercised stock options and sold shares to cover the exercise price and tax obligations on June 4, 2024.

Summary

• On June 4, 2024, Gary Charles Robb, the Chief Business Officer of Corcept Therapeutics, exercised stock options to purchase 14,000 shares of common stock at a price of $3.29 per share.
• Robb then sold 8,174 shares at $32.87 per share to cover the exercise price and associated tax liabilities.
• Following these transactions, Robb directly owns 28,941 shares of Corcept Therapeutics common stock.
• He also indirectly owns 7,700, 8,700 and 8,700 shares through custodial accounts for his children.
• Robb also holds options for 36,037 shares.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing an executive's stock option exercise and share sale. It doesn't inherently convey positive or negative sentiment about the company's performance or future prospects.

Industry Context

This filing is a routine disclosure of insider transactions, which are common for executives who receive stock options as part of their compensation. These transactions are closely watched by investors for signals about management's confidence in the company's future prospects.

Comparison to Industry Standards

• Executive compensation packages often include stock options to align management's interests with those of shareholders.
• The exercise of options and subsequent sale of shares to cover costs is a standard practice among executives at publicly traded companies.
• Similar transactions are regularly reported by executives at comparable pharmaceutical and biotechnology companies.

Stakeholder Impact

• The transaction has a minimal direct impact on shareholders, as it is a routine executive stock option exercise and sale.
• The sale of shares could slightly increase the available float in the market.

Key Dates